
Genentech USA Inc - Strategic SWOT Analysis Review
Description
Genentech USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
Genentech Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious and life-threatening diseases. It offers drugs in various therapeutic areas, including oncology, immunology, ophthalmology, neurology, infectious disease, metabolism, primary care, and specialty care. Genentech also offers patient support services such as co-pay programs, health insurance, and independent co-pay assistance, among others. The company's products are offered to patients with complex health conditions mainly in the US healthcare market. It operates a manufacturing facility in the US. Genentech is headquartered in South San Francisco, California, the US.
Genentech USA Inc Key Recent Developments
May 28,2025: Novellia Launches AI-Powered, Cross-Industry Research Initiative to Transform Breast Cancer Care
May 21,2025: Orionis Biosciences Announces Strategic Partnership with Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer
Apr 24,2025: Repertoire and Genentech to develop autoimmune disease therapies
Nov 05,2024: Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024
Reasons to Buy
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Genentech Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious and life-threatening diseases. It offers drugs in various therapeutic areas, including oncology, immunology, ophthalmology, neurology, infectious disease, metabolism, primary care, and specialty care. Genentech also offers patient support services such as co-pay programs, health insurance, and independent co-pay assistance, among others. The company's products are offered to patients with complex health conditions mainly in the US healthcare market. It operates a manufacturing facility in the US. Genentech is headquartered in South San Francisco, California, the US.
Genentech USA Inc Key Recent Developments
May 28,2025: Novellia Launches AI-Powered, Cross-Industry Research Initiative to Transform Breast Cancer Care
May 21,2025: Orionis Biosciences Announces Strategic Partnership with Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer
Apr 24,2025: Repertoire and Genentech to develop autoimmune disease therapies
Nov 05,2024: Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Table of Contents
39 Pages
- Section 1 - About the Company
- Genentech USA Inc - Key Facts
- Genentech USA Inc - Key Employees
- Genentech USA Inc - Major Products and Services
- Genentech USA Inc - History
- Genentech USA Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Genentech USA Inc - Business Description
- Genentech USA Inc - SWOT Analysis
- SWOT Analysis - Overview
- Genentech USA Inc - Strengths
- Genentech USA Inc - Weaknesses
- Genentech USA Inc - Opportunities
- Genentech USA Inc - Threats
- Genentech USA Inc - Key Competitors
- Section 3 – Company’s Lifesciences Financial Deals and Alliances
- Genentech USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Genentech USA Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Genentech USA Inc, Recent Deals Summary
- Section 4 – Company’s Recent Developments
- May 28, 2025: Novellia Launches AI-Powered, Cross-Industry Research Initiative to Transform Breast Cancer Care
- May 21, 2025: Orionis Biosciences Announces Strategic Partnership with Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer
- Apr 24, 2025: Repertoire and Genentech to develop autoimmune disease therapies
- Nov 05, 2024: Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024
- Jun 24, 2024: Ophthalmologists Favor Genentech’s Vabysmo and Regeneron’s Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
- Jan 31, 2024: Genentech and C3 AI Improve the Complex Biologics Manufacturing Process with AI
- Section 5 – Appendix
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Genentech USA Inc, Key Facts
- Genentech USA Inc, Key Employees
- Genentech USA Inc, Major Products and Services
- Genentech USA Inc, History
- Genentech USA Inc, Other Locations
- Genentech USA Inc, Key Competitors
- Genentech USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Genentech USA Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Genentech USA Inc, Recent Deals Summary
- List of Figures
- Genentech USA Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Genentech USA Inc, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.